.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Accenture
Colorcon
Mallinckrodt
Merck
QuintilesIMS
Express Scripts
Federal Trade Commission
Deloitte
Covington

Generated: June 27, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,772,209

« Back to Dashboard

Which drugs does patent 7,772,209 protect, and when does it expire?


Patent 7,772,209 protects ALIMTA and is included in one NDA. There have been four Paragraph IV challenges on Alimta.

Protection for ALIMTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 7,772,209

Title:Antifolate combination therapies
Abstract:A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent.
Inventor(s): Niyikiza; Clet (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:11/776,329
Patent Claim Types:
see list of patent claims
Use; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Lilly
ALIMTA
pemetrexed disodium
INJECTABLE;IV (INFUSION)021462-002Sep 7, 2007RXYesYes7,772,209*PED► SubscribeY
Lilly
ALIMTA
pemetrexed disodium
INJECTABLE;IV (INFUSION)021462-001Feb 4, 2004RXYesYes7,772,209*PED► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Chinese Patent Office
Farmers Insurance
Citi
Merck
Novartis
Colorcon
Chubb
Deloitte
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot